Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.87 |
| ▸ | MMP2 | P08253 | 13/20 | 0.87 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.58 |
| ▸ | MMP8 | P22894 | 2/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.58 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562688 | 1.00 | MMP9 (0.87) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL9753071 | 0.90 | MMP9 (0.71) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL29928063 | 0.89 | MMP9 (0.70) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL10585071 | 0.87 | MMP9 (0.76) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL8001084 | 0.87 | MMP9 (0.76) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL457772 | 0.87 | MMP9 (0.76) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| Hydrochloric Acid SCHEMBL9087107 | 0.86 | MMP9 (0.74) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL7980130 | 0.86 | MMP9 (0.67) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL28212986 | 0.86 | MMP9 (0.67) | MMP9MMP2ADAMTS4MMP8MMP13 | |
| SCHEMBL20008635 | 0.86 | MMP9 (0.67) | MMP9MMP2ADAMTS4MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040062773-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES INC. | 2004-04-01 | — | — | US | claimed |
| EP-0784469-B1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 2004-03-24 | — | — | EP | claimed |
| US-6610329-B2 | Using acylated amino acid as carrier | EMISPHERE TECHNOLOGIES INC. | 2003-08-26 | — | — | US | claimed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | claimed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0784469-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | claimed |
| US-12624109-B2 | αv-integrin targeted small molecule drug conjugates | TARGETTHERA LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240376212-A1 | ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES | TARGETTHERA LLC | 2024-11-14 | — | — | US | disclosed |
| EP-1390053-A2 | HCG FORMULATION | Acevedo, Hernan F. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002085311-A2 | HCG FORMULATION | ACEVEDO HERNAN F (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020001591-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | MMP9 2979/4885MMP2 2444/4885ADAMTS4 3212/4885 |
| US-20040062773-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | MMP9 2979/4885MMP2 2444/4885ADAMTS4 3212/4885 |
| US-12624109-B2 | αv-integrin targeted small molecule drug conjugates | ITGA1, ITGB1, ITGA2 | MMP9 1841/4885MMP2 2240/4885ADAMTS4 2648/4885 |
| US-20240376212-A1 | ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES | ITGA1, ITGAL, ITGAV | MMP9 2266/4885MMP2 2229/4885ADAMTS4 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.